Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated intravenous levosimendan in hospitalized patients with severe dilated cardiomyopathy and heart failure
ChiCTR2100046778Phase 4Recruiting
- Sponsor
- Fuwai Hospital
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in dilated cardiomyopathy (DCM) and heart failure (HF) comparing Placebo control group with Intermittent repeated levosimendan group (2 arms). Primary endpoint: Incidence of major adverse cardiac events due to cardiovascular death or worsening heart failure. Started Jul 2021; status: recruiting.
02
Drugs
levosimendan
03
Conditions
dilated cardiomyopathy (DCM)heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2100046778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046778.